Product Reports Resources Pricing Login Book a demo

Immatics biotechnologies

Biotech & Life Sciences · Tübingen, Germany · Founded 2000 · Public via SPAC 2020

Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets

Valuation $677M
Revenue $47M

Investors

17 investors on Immatics biotechnologies's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
EMBL Ventures
3i Group
Wellington Partners
L-Bank
Vinci Capital
Grazia Equity
Series B+ 11 investors entered at this stage
Bristol-Myers Squibb
DH Capital
MIG Capital
b2venture
KfW
dievini Hopp Biotech holding
Celgene
Swisscom Ventures
AT Impf GmbH
Amgen
Dezima Pharma

Global footprint

Where Immatics biotechnologies has talent and traffic

Workforce by country
7 countries with
team presence
🇩🇪 Germany55.9%
🇺🇸 United States42.8%
🇨🇭 Switzerland0.4%
🇳🇱 Netherlands0.2%
🇮🇳 India0.2%
Top 5 of 7 shown
Web traffic by country
26K monthly visits
across markets
🇺🇸 United States81.5%
🇬🇧 United Kingdom6.5%
🇩🇪 Germany4.6%
🇮🇳 India4.2%
🇨🇦 Canada3.1%
Top 5 markets shown

Talent graph

The shape of Immatics biotechnologies's talent

Dealroom maps Immatics biotechnologies's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

14 standout operatorsDealroom-flagged across the org
14 AI specialistsincl. 6 core researchers
649 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Immatics biotechnologies's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$272M patent portfolio · 204 active families

Estimated portfolio value
$272M
40.2% of market cap · 2.9× smaller than top peer BioNTech ($788M)
204 active patent families
Where Immatics biotechnologies innovates Anti tumourCarcinosisEpitopeImmunotherapyMolecular biology

Where Immatics biotechnologies concentrates vs peers

Each axis is a top-10 topic across Immatics biotechnologies and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immatics biotechnologies

An AI-synthesized read of the highest-engagement posts about Immatics biotechnologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immatics biotechnologies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.